Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
Doorduijn JK, Zijlstra JM, Lugtenburg PJ, Kersten MJ, Böhmer LH, Minnema MC, MacKenzie MA, van Marwijk Kooij R, de Jongh E, Snijders TJF, de Weerdt O, van Gelder M, Hoogendoorn M, Leys RBL, Kibbelaar RE, de Jong D, Chitu DA, Van't Veer MB, Kluin-Nelemans HC. Doorduijn JK, et al. Among authors: kersten mj. Br J Haematol. 2020 Aug;190(3):385-393. doi: 10.1111/bjh.16567. Epub 2020 Mar 9. Br J Haematol. 2020. PMID: 32150297 Free PMC article. Clinical Trial.
Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).
Lugtenburg PJ, de Nully Brown P, van der Holt B, D'Amore FA, Koene HR, de Jongh E, Fijnheer R, van Esser JW, Böhmer LH, Pruijt JF, Verhoef GE, Hoogendoorn M, Bilgin MY, Nijland M, van der Burg-de Graauw NC, Oosterveld M, Jie KG, Larsen TS, van der Poel MW, Leijs MB, Silbermann MH, van Marwijk Kooy M, Beeker A, Kersten MJ, Doorduijn JK, Tick LW, Brouwer RE, Lam KH, Burggraaff CN, de Keizer B, Arens AI, de Jong D, Hoekstra OS, Zijlstra-Baalbergen JM. Lugtenburg PJ, et al. Among authors: kersten mj. J Clin Oncol. 2020 Oct 10;38(29):3377-3387. doi: 10.1200/JCO.19.03418. Epub 2020 Jul 30. J Clin Oncol. 2020. PMID: 32730183 Clinical Trial.
Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.
Oosten LEM, Chamuleau MED, Thielen FW, de Wreede LC, Siemes C, Doorduijn JK, Smeekes OS, Kersten MJ, Hardi L, Baars JW, Demandt AMP, Stevens WBC, Nijland M, van Imhoff GW, Brouwer R, Uyl-de Groot CA, Kluin PM, de Jong D, Veelken H. Oosten LEM, et al. Among authors: kersten mj. Ann Hematol. 2018 Feb;97(2):255-266. doi: 10.1007/s00277-017-3167-7. Epub 2017 Dec 6. Ann Hematol. 2018. PMID: 29209924 Free PMC article.
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.
Deenik W, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Kluin-Nelemans HC, Verdonck LF, Ferrant A, Schattenberg AV, Janssen JJ, Sonneveld P, van Marwijk Kooy M, Wittebol S, Willemze R, Wijermans PW, Westveer PH, Beverloo HB, Valk P, Löwenberg B, Ossenkoppele GJ, Cornelissen JJ. Deenik W, et al. Among authors: kersten mj. Blood. 2008 Mar 1;111(5):2581-8. doi: 10.1182/blood-2007-08-107482. Epub 2008 Jan 2. Blood. 2008. PMID: 18172005 Free article. Clinical Trial.
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.
Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk Kooy M, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P. Goldschmidt H, et al. Among authors: kersten mj. Leukemia. 2018 Feb;32(2):383-390. doi: 10.1038/leu.2017.211. Epub 2017 Jul 4. Leukemia. 2018. PMID: 28761118 Clinical Trial.
Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome.
Minnema MC, van de Donk NW, Zweegman S, Hegenbart U, Schonland S, Raymakers R, Zijlmans JM, Kersten MJ, Bos GM, Lokhorst HM. Minnema MC, et al. Among authors: kersten mj. Bone Marrow Transplant. 2008 May;41(9):779-84. doi: 10.1038/sj.bmt.1705982. Epub 2008 Jan 14. Bone Marrow Transplant. 2008. PMID: 18195681
278 results